Mini Review - Asian Journal of Biomedical and Pharmaceutical Sciences (2020) Volume 10, Issue 72
Mini Review: Heparin treatment in COVID-19: Where are we?
Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome with a high mortality rate; it is caused by SARS-CoV-2, a new virus of the Coronaviridae family that emerged in Wuhan, Hubei, China, in December 2019 and rapidly spread worldwide until declared by the World Health Organization a global pandemic on March 11th, 2020. The race for an effective drug to prevent or treat SARS-CoV-2 infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Despite scientific effort, no pharmacological intervention has proven definitively beneficial, and care is primarily supportive.Author(s): Rizzo M, Pezone I, Amicone M, Riccio E, Pisani A*